Teva Wins Ruling Narrowing Antitrust Case Over Gilead HIV Drugs

Jan. 14, 2022, 8:41 PM

Teva Pharmaceutical Industries Ltd. succeeded in scaling back its potential antitrust exposure for allegedly helping delay generic versions of Gilead Sciences Inc.'s blockbuster HIV drugs, when a federal judge in San Francisco ruled that some claims against Teva were filed too late.

Judge Edward M. Chen narrowed the allegations against Teva, one of several pharmaceutical companies accused of taking a “reverse payment” from Gilead to shelve its generic version of Truvada as part of a settlement resolving patent infringement litigation.

“Reverse payment” settlements—so called because they involve concessions from a patent plaintiff to a defendant, rather than in the usual ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.